Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy

<div class="floats-full-page floats-full-page-figure"><h2>Figure 2</h2><div class="floats-full-page-caption"><table>(a) CD4+/CD38+/DR+, (b) CD8+/CD38+/DR+, percentage of apoptotic T cells, (c) CD4+/CD95+, (d) CD8+/CD95+. Line represents median; <svg height="13.825" id="M22" style="vertical-align:-0.16379pt" version="1.1" viewbox="0 0 72.012497 13.825" width="72.012497" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.012,-0,0,-.012,.062,5.4)"><path d="M433 39l-85 -51q-27 0 -47 20q-16 16 -24 44q-5 -3 -24 -16.5t-27 -18.5t-23 -13.5t-25 -12t-19 -3.5q-52 0 -86 36.5t-34 85.5q0 71 81 99q128 43 155 65v17q0 54 -23 83.5t-62 29.5q-28 0 -45 -19t-29 -66q-7 -23 -29 -23q-15 0 -29 13t-14 30t31 40q25 19 68.5 40.5&#10;t81.5 29.5q49 0 82 -27q45 -39 45 -123v-185q0 -60 35 -60q18 0 36 11zM275 84v156q-12 -6 -49 -23t-41 -19q-31 -14 -46 -31t-15 -43q0 -35 22.5 -55.5t48.5 -20.5q19 0 42 10.5t38 25.5z" id="x61"></path></g>
<g transform="matrix(.017,-0,0,-.017,5.913,13.562)"><path d="M956 650v-28q-52 -7 -69 -22.5t-39 -77.5q-60 -175 -165 -533h-31l-175 499h-2l-163 -499h-31l-164 535q-18 60 -36 76.5t-65 21.5v28h243v-28q-53 -7 -63 -18.5t3 -49.5l122 -412h2l162 499h29l175 -500h2q87 277 113 401q12 45 0.5 59t-68.5 21v28h220z" id="x57"></path></g><g transform="matrix(.017,-0,0,-.017,21.772,13.562)"><path d="M135 536q-20 0 -35 15.5t-15 35.5q0 22 15 37t36 15t35.5 -15t14.5 -37q0 -21 -15 -36t-36 -15zM252 0h-220v26q48 5 59 17t11 63v206q0 47 -9 58t-54 18v24q78 12 142 39v-345q0 -51 11.5 -63t59.5 -17v-26z" id="x69"></path></g><g transform="matrix(.017,-0,0,-.017,26.396,13.562)"><path d="M238 0h-223v26q48 5 60 17t12 61v473q0 50 -10.5 60.5t-58.5 15.5v24q73 8 148 35v-608q0 -49 11.5 -61t60.5 -17v-26z" id="x6C"></path></g><g transform="matrix(.017,-0,0,-.017,30.697,13.562)"><path d="M390 111l17 -21q-34 -45 -80 -73.5t-89 -28.5q-91 0 -146 62t-55 147q0 118 101 195q74 57 149 57h1q59 0 90 -27q16 -14 16 -30q0 -15 -12 -29t-21 -14q-8 0 -19 11q-44 41 -101 41q-52 0 -87.5 -42.5t-35.5 -117.5q0 -49 15 -87t39 -58t49 -30t48 -10q33 0 60.5 12&#10;t60.5 43z" id="x63"></path></g><g transform="matrix(.017,-0,0,-.017,37.887,13.562)"><path d="M257 449q92 0 154 -65t62 -158q0 -112 -67 -175t-150 -63q-98 0 -158.5 66.5t-60.5 154.5q0 59 21 106.5t54.5 75.5t71 43t73.5 15zM244 416q-48 0 -81 -47t-33 -128q0 -96 38 -158t99 -62q51 0 82 43.5t31 139.5q0 91 -36 151.5t-100 60.5z" id="x6F"></path></g><g transform="matrix(.017,-0,0,-.017,46.302,13.562)"><path d="M474 0h-214v26q32 4 39 12t-5 28l-74 117q-39 -58 -64 -106q-16 -25 -10 -35t44 -16v-26h-186v26q46 6 64 17t48 49t85 120l-87 136q-23 36 -40 47t-58 16v26h199v-26q-31 -4 -36.5 -12.5t9.5 -29.5l59 -93q37 56 58 94q13 23 7 30t-40 11v26h183v-26q-47 -5 -65 -13.5&#10;t-45 -39.5q-24 -29 -78 -110l97 -148q28 -43 46.5 -55.5t63.5 -18.5v-26z" id="x78"></path></g><g transform="matrix(.017,-0,0,-.017,54.189,13.562)"><path d="M257 449q92 0 154 -65t62 -158q0 -112 -67 -175t-150 -63q-98 0 -158.5 66.5t-60.5 154.5q0 59 21 106.5t54.5 75.5t71 43t73.5 15zM244 416q-48 0 -81 -47t-33 -128q0 -96 38 -158t99 -62q51 0 82 43.5t31 139.5q0 91 -36 151.5t-100 60.5z" id="x6F"></path></g><g transform="matrix(.017,-0,0,-.017,62.654,13.562)"><path d="M524 0h-209v26q44 5 55 18t11 65v167q0 114 -91 114q-50 0 -109 -51v-235q0 -50 10 -61.5t55 -16.5v-26h-217v26q51 5 62 17t11 61v206q0 47 -9.5 58.5t-50.5 19.5v23q82 15 139 40v-79l67 47q47 30 83 30q60 0 94.5 -40t34.5 -112v-193q0 -50 10 -61.5t54 -16.5v-26z&#10;" id="x6E"></path></g>
</svg> rank-sum test; BL: baseline.</table></div><div class="floats-full-page-content"><table class="table-group" width="800px"><tr class="fig-image" id="a"><td><img alt="358294.fig.002a" src="https://static-01.hindawi.com/articles/isrn/volume-2013/358294/figures/358294.fig.002a.jpg" /></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(a) </b></td></tr></table></td></tr><tr class="fig-image" id="b"><td><img alt="358294.fig.002b" src="https://static-01.hindawi.com/articles/isrn/volume-2013/358294/figures/358294.fig.002b.jpg" /></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(b) </b></td></tr></table></td></tr><tr class="fig-image" id="c"><td><img alt="358294.fig.002c" src="https://static-01.hindawi.com/articles/isrn/volume-2013/358294/figures/358294.fig.002c.jpg" /></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(c) </b></td></tr></table></td></tr><tr class="fig-image" id="d"><td><img alt="358294.fig.002d" src="https://static-01.hindawi.com/articles/isrn/volume-2013/358294/figures/358294.fig.002d.jpg" /></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(d) </b></td></tr></table></td></tr></table></div></div>

Figure 2 | Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy

title

Figure 2: Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy

description

Figure 2

About this journal

Journal profile

Meet the editorial board

Editor spotlight

Find out more

This journal's articles appear in a wide range of abstracting and indexing databases, and are covered by numerous other services that aid discovery and access. Find out more about where and how the content of this journal is available.

International Scholarly Research Notices

Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy

Figure 2